Catalyst Wire Dossier Catalyst Wire Dossier

Xeomin/Bocouture

incobotulinumtoxinA · Merz Pharmaceuticals GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Xeomin/Bocouture, covering 2012-02-10 to 2012-02-10. Get the full timeline:

Most recent: Clinical Trial Update: NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines [Phase 3]

See pricing